Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Forte Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Forte Biosciences, Inc.

FBRX

Forte Biosciences, Inc.

About Forte Biosciences, Inc.

Forte Biosciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies targeting autoimmune diseases. Its lead candidate, FB102, is a monoclonal antibody aimed at conditions like celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company focuses on innovative biologics, regulatory approval processes, and strategic partnerships to address unmet medical needs in autoimmune markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Forte Biosciences, Inc.

1
1
Forte Biosciences, Inc. Forte Biosciences Reports $22.1 Million Net Loss in Q1 2026, Completes $172.5 Million Public Offering

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Forte Biosciences, Inc. Forte Biosciences Reports $69.4 Million Net Loss and Progress in FB102 Clinical Trials

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Forte Biosciences, Inc. Forte Biosciences Reports $17.7 Million Net Loss in Q3 2025, Increases Cash Reserves to $93.4 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Forte Biosciences, Inc. Forte Biosciences Reports $11.2 Million Net Loss and $106.1 Million Cash Reserves for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Forte Biosciences, Inc. Forte Biosciences Reports $15.7 Million Net Loss in Q1 2025 Amid Increased R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Forte Biosciences, Inc. Forte Biosciences Reports $35.5 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Forte Biosciences, Inc. Forte Biosciences Reports Significant Financial Decline, Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments